Ubs Group Ag Virios Therapeutics, Inc. Transaction History

Ubs Group Ag

  • $452 Billion
  • Q3 2024

A detailed history of Ubs Group Ag transactions in Virios Therapeutics, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 186,062 shares of VIRI stock, worth $826,115. This represents 0.0% of its overall portfolio holdings.

Number of Shares
186,062
Previous 151,779 22.59%
Holding current value
$826,115
Previous $33,000 6.06%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$0.17 - $0.29 $5,828 - $9,942
34,283 Added 22.59%
186,062 $31,000
Q2 2024

Aug 13, 2024
BUY
$0.18 - $0.58 $27,320 - $88,031
151,779 New
151,779 $33,000
Q4 2023

Feb 09, 2024
BUY
$0.46 - $0.9 $1,196 - $2,340
2,600 New
2,600 $1,000
Q2 2023

Aug 11, 2023
SELL
$0.35 - $1.94 $479 - $2,659
-1,371 Reduced 83.8%
265 $0
Q1 2023

May 12, 2023
BUY
$0.24 - $0.44 $392 - $719
1,636 New
1,636 $0
Q3 2022

Nov 10, 2022
BUY
$0.37 - $8.77 $15,185 - $359,929
41,041 New
41,041 $16,000
Q2 2022

Aug 10, 2022
SELL
$3.31 - $4.89 $46,793 - $69,129
-14,137 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$4.48 - $6.92 $53,253 - $82,258
11,887 Added 528.31%
14,137 $63,000
Q4 2021

Feb 14, 2022
BUY
$4.07 - $6.12 $9,157 - $13,770
2,250 New
2,250 $12,000
Q3 2021

Nov 15, 2021
SELL
$4.61 - $6.56 $61,386 - $87,352
-13,316 Closed
0 $0
Q2 2021

Aug 13, 2021
BUY
$4.71 - $6.95 $62,718 - $92,546
13,316 New
13,316 $84,000
Q1 2021

May 12, 2021
SELL
$5.01 - $8.84 $16,643 - $29,366
-3,322 Closed
0 $0
Q4 2020

Feb 11, 2021
BUY
$7.51 - $16.71 $24,948 - $55,510
3,322 New
3,322 $25,000

Others Institutions Holding VIRI

# of Institutions
28
Shares Held
1.12M
Call Options Held
0
Put Options Held
0
View Full List

About Virios Therapeutics, Inc.

VIRI Quotes by TradingView
  • Ticker VIRI
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 18,330,400
  • Market Cap $81.4M
  • Description
  • Virios Therapeutics, Inc., a development-stage biotechnology company, focuses on developing antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It is also developing IMC...
More about VIRI
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email